Filing Flows › Indivior Pharmaceuticals (INDV) › Q4 2025
Indivior Pharmaceuticals (INDV) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 26, 2026
Indivior Pharmaceuticals (INDV) reported revenue of $358M for the fourth quarter 2025 (Q4 2025), +20% from a year earlier and +14% from the quarter before. Operating margin was 22.6%, net earnings $102M (28.5% of revenue).
Indivior Pharmaceuticals, Q4 2025: revenue $358M (+20% year over year), operating margin 22.6%, net earnings $102M, operating cash flow −$221M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $358M | +14% | +20% |
| Gross profit | $292M | +27% | +17% |
| Operating profit | $81.0M | +88% | +76% |
| Net earnings | $102M | +143% | +386% |
| Operating cash flow | −$221M | — | — |
What changed
Revenue was $358.0M in Q4 2025, up 20% year over year and up 14% from the previous quarter.
Gross margin was 81.6%, down 2.0 points from a year earlier. Operating profit was $81.0M, a 22.6% margin (up 7.2 points year over year). Of the extra revenue versus a year earlier, 59% reached operating profit, above the 15% margin then. Operating expenses grew 3% against revenue growth of 20%. Net earnings were $102.0M, up 386% year over year. The effective tax rate was -25.9%.
Operating cash flow was −$221.0M. Non-cash charges added back $2.0M of depreciation and amortization and $5.0M of share-based compensation. Working capital and other items used $330.0M. Capital expenditures of $24.0M exceeded it, leaving free cash flow of −$245.0M.
Questions
What was Indivior Pharmaceuticals' revenue in the fourth quarter 2025?
Indivior Pharmaceuticals (INDV) reported revenue of $358M for the fourth quarter 2025 (Q4 2025), +20% from a year earlier and +14% from the quarter before.
Was Indivior Pharmaceuticals profitable in the fourth quarter 2025?
Operating profit was $81.0M (22.6% of revenue) and net earnings $102M.